Influenza Vaccination. Health Impact and Cost Effectiveness Among Adults Aged 50 to 64 and 65 and Older

American Journal of Preventive Medicine

Volumn 31, Issue 1, 2006, Pages 72-79

  Maciosek, Michael V ^a   Solberg, Leif I ^a   Coffield, Ashley B ^b   Edwards, Nichol M ^a   Goodman, Michael J ^a  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^b Partnership for Prevention   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; ZANAMIVIR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; TRAVEL; UNITED STATES;

AGED; COST-BENEFIT ANALYSIS; HEALTH PRIORITIES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 33745461186     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2006.03.008     Document Type: Article

References (68)

1. Bridges C.B., Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., and Singleton J.A. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 52 (2003) 1-34 (quiz CE1-4)
2. Centers of Disease Control and Prevention. Notice to readers. recommended adult immunization schedule-United States, 2002-2003. MMWR Morb Mortal Wkly Rep 51 (2002) 904-908
3. Centers of Disease Control and Prevention. Early release of selected estimates based on data from the January-March 2004 Health Interview Survey (2004). http://www.cdc.gov/nchs/data/nhis/earlyrelease/200409_04.pdf September. Available at: www.cdc.gov/nchs/data/nhis/earlyrelease/200409_04.pdf Accessed October 29, 2004.
4. Centers of Disease Control and Prevention. Influenza vaccination levels among persons aged ≥65 years and among persons aged 18-64 years with high-risk conditions-United States, 2003. MMWR Morb Mortal Wkly Rep 54 (2005) 1045-1049
5. Maciosek M.V., Coffield A.B., Edwards N.M., Flottemesch T.J., Goodman M.J., and Solberg L.I. Priorities among effective clinical preventive services. results of a systematic review and analysis. Am J Prev Med 31 (2006) 52-61
6. Solberg L.I., Maciosek M.V., Edwards N.M., Khandchandani H.S., and Goodman M.J. Repeated tobacco-use screening and intervention in clinical practice. health impact and cost effectiveness. Am J Prev Med 31 (2006) 62-71
7. Maciosek M.V., Solberg L.I., Coffield A.B., Edwards N.M., and Goodman M.J. The health impact and cost effectiveness of colorectal cancer screening. Am J Prev Med 31 (2006) 80-89
8. Maciosek M.V., Edwards N.M., Coffield A.B., et al. Priorities among effective clinical preventive services. methods. Am J Prev Med 31 (2006) 90-96
9. Coffield A.B., Maciosek M.V., McGinnis J.M., et al. Priorities among recommended clinical preventive services. Am J Prev Med 21 (2001) 1-9
10. Maciosek M.V., Coffield A.B., McGinnis J.M., et al. Methods for priority setting among clinical preventive services. Am J Prev Med 21 (2001) 10-19
11. Maciosek M.V., Edwards N.M., Solberg L.I., et al. Technical report of the National Commission on Prevention Priorities: methods update for priority setting among clinical preventive services (2005). http://www.prevent.org Available at: www.prevent.org.
12. Ahmed A.E., Nicholson K.G., and Nguyen-van Tam J.S. Reduction in mortality associated with influenza vaccine during 1989-1990 epidemic. Lancet 346 (1995) 591-595
13. Ahmed A.H., Nicholson K.G., Nguyen-van Tam J.S., and Pearson J.C. Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-1990 epidemic. Epidemiol Infect 118 (1997) 27-33
14. Arden N.H., Patriarca P.A., Fasano M.B., et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med 148 (1988) 865-868
15. Barker W.H., and Mullooly J.P. Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths. JAMA 244 (1980) 2547-2549
16. Bridges C.B., Thompson W.W., Meltzer M.I., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults. a randomized controlled trial. JAMA 284 (2000) 1655-1663
17. Cartter M.L., Renzullo P.O., Helgerson S.D., Martin S.M., and Jekel J.F. Influenza outbreaks in nursing homes. how effective is influenza vaccine in the institutionalized elderly?. Infect Control Hosp Epidemiol 11 (1990) 473-478
18. Edwards K.M., Dupont W.D., Westrich M.K., Plummer Jr. W.D., Palmer P.S., and Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169 (1994) 68-76
19. Fedson D.S., Wajda A., Nicol J.P., Hammond G.W., Kaiser D.L., and Roos L.L. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 270 (1993) 1956-1961
20. Fleming D.M., Watson J.M., Nicholas S., Smith G.E., and Swan A.V. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-1990 using a general practice database. Epidemiol Infect 115 (1995) 581-589
21. Foster D.A., Talsma A., Furumoto-Dawson A., et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 136 (1992) 296-307
22. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., and Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272 (1994) 1661-1665
23. Gravenstein S., Drinka P., Duthie E.H., et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 42 (1994) 245-251
24. Gross P.A., Quinnan G.V., Rodstein M., et al. Association of influenza immunization with reduction in mortality in an elderly population. A prospective study. Arch Intern Med 148 (1988) 562-565
25. Howells C.H., Vesselinova-Jenkins C.K., Evans A.D., and James J. Influenza vaccination and mortality from bronchopneumonia in the elderly. Lancet 1 (1975) 381-383
26. Meiklejohn G., and Hall H. Unusual outbreak of influenza A in a Wyoming nursing home. J Am Geriatr Soc 35 (1987) 742-746
27. Meiklejohn G., Hoffman R., and Graves P. Effectiveness of influenza vaccine when given during an outbreak of influenza A/H3N2 in a nursing home. J Am Geriatr Soc 37 (1989) 407-410
28. Mullooly J.P., Bennett M.D., Hornbrook M.C., et al. Influenza vaccination programs for elderly persons. cost-effectiveness in a health maintenance organization. Ann Intern Med 121 (1994) 947-952
29. Nichol K.L., Margolis K.L., Wouremna J., and von Sternberg T. Effectiveness of influenza vaccine in the elderly. Gerontology 42 (1996) 274-279
30. Nichol K.L., Margolis K.L., Wuorenma J., and von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331 (1994) 778-784
31. Nichol K.L., Mendelman P.M., Mallon K.P., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults. a randomized controlled trial. JAMA 282 (1999) 137-144
32. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., and Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348 (2003) 1322-1332
33. Nichol K.L., Wuorenma J., and von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158 (1998) 1769-1776
34. Nordin J., Mullooly J., Poblete S., et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon. data from 3 health plans. J Infect Dis 184 (2001) 665-670
35. Patriarca P.A., Weber J.A., Parker R.A., et al. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 253 (1985) 1136-1139
36. Taylor J.L., Dwyer D.M., Coffman T., Groves C., Patel J., and Israel E. Nursing home outbreak of influenza A (H3N2). evaluation of vaccine efficacy and influenza case definitions. Infect Control Hosp Epidemiol 13 (1992) 93-97
37. Treanor J.J., Mattison H.R., Dumyati G., et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 117 (1992) 625-633
38. Weingarten S., Staniloff H., Ault M., Miles P., Bamberger M., and Meyer R.D. Do hospital employees benefit from the influenza vaccine? A placebo-controlled clinical trial. J Gen Intern Med 3 (1988) 32-37
39. Allsup S., Haycox A., Regan M., and Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine 23 (2004) 639-645
40. Kawai N., Ikematsu H., Iwaki N., et al. A prospective, Internet-based study of the effectiveness and safety of influenza vaccination in the 2001-2002 influenza season. Vaccine 21 (2003) 4507-4513
41. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., and Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people. a systematic review. Lancet 366 (2005) 1165-1174
42. Nichol K.L. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 161 (2001) 749-759
43. Frank J.W., McMurray L., and Henderson M. Influenza vaccination in the elderly. 2. The economics of sending reminder letters. CAMJ 132 (1985) 516-518 521
44. Lee P.Y., Matchar D.B., Clements D.A., Huber J., Hamilton J.D., and Peterson E.D. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 137 (2002) 225-231
45. Maucher J.M., and Gambert S.R. Cost-effective analysis of influenza vaccination in the elderly. Age 13 (1990) 81-85
46. Meltzer M.I., Cox N.J., and Fukuda K. The economic impact of pandemic influenza in the United States. priorities for intervention. Emerg Infect Dis 5 (1999) 659-671
47. Nichol K.L., and Goodman M. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years. Vaccine 20 suppl 2 (2002) S21-S24
48. Nichol K.L., and Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. Pharmacoeconomics 16 suppl 1 (1999) 63-71
49. Nichol K.L., Mallon K.P., and Mendelman P.M. Cost benefit of influenza vaccination in healthy, working adults. an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 21 (2003) 2207-2217
50. Riddiough M.A., Sisk J.E., and Bell J.C. Influenza vaccination. JAMA 249 (1983) 3189-3195
51. Scott W.G., and Scott H.M. Economic evaluation of vaccination against influenza in New Zealand. Pharmacoeconomics 9 (1996) 51-60
52. Centers of Disease Control and Prevention. Final results. Medicare influenza vaccine demonstration-selected states, 1988-1992. MMWR Morb Mortal Wkly Rep 42 (1993) 601-604
53. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
54. Heilman C., and La Montagne J.R. Influenza. status and prospects for its prevention, therapy, and control. Pediatr Clin North Am 37 (1990) 669-688
55. Cox N.J., and Fukuda K. Influenza. Infect Dis Clin North Am 12 (1998) 27-38
56. Arias E. United States life tables, 2000. Natl Vital Stat Rep 51 (2002) 1-38
57. Singleton J.A., Greby S.M., Wooten K.G., Walker F.J., and Strikas R. Influenza, pneumococcal, and tetanus toxoid vaccination of adults-United States, 1993-1997. MMWR CDC Surveill Summ 49 (2000) 39-62
58. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage levels among persons aged greater than or equal to 65 years-United States, 1973-1993. MMWR Morb Mortal Wkly Rep 44 (1995) 506-507 513-5
59. Keitel W.A., Cate T.R., Couch R.B., Huggins L.L., and Hess K.R. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five-year period. Vaccine 15 (1997) 1114-1122
60. Monto A.S., Robinson D.P., Herlocher M.L., Hinson Jr. J.M., Elliott M.J., and Crisp A. Zanamivir in the prevention of influenza among healthy adults. a randomized controlled trial. JAMA 282 (1999) 31-35
61. Herman C.J., Speroff T., and Cebul R.D. Improving compliance with immunization in the older adult. results of a randomized cohort study. J Am Geriatr Soc 42 (1994) 1154-1159
62. van Essen G.A., Kuyvenhoven M.M., and de Melker R.A. Why do healthy elderly people fail to comply with influenza vaccination?. Age Ageing 26 (1997) 275-279
63. Igoe G., Bedford D., Howell F., and Collins S. How to improve the uptake of influenza vaccination in older persons at risk. Ir J Med Sci 168 (1999) 107-108
64. van Essen G.A., Kuyvenhoven M.M., and de Melker R.A. Compliance with influenza vaccination. Its relation with epidemiologic and sociopsychological factors. Arch Fam Med 6 (1997) 157-162 discussion 163
65. Centers for Disease Control and Prevention. CDC Wonder database, compressed mortality file-underlying cause-of-death. Available at: http://wonder.cdc.gov/wonder/cgi-bin/asp/MortRates.asp. Accessed February 2004.
66. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
67. U.S. Department of Labor, Bureau of Labor Statistics. Employer costs for employee compensation historical listing (annual), 1986-2001 (2002), Bureau of Labor Statistics, June 19, Washington DC
68. Simonsen L., Reichert T.A., Viboud C., Blackwelder W.C., Taylor R.J., and Miller M.A. Impact of influenza vaccination on seasonal mortality in the U.S. elderly population. Arch Intern Med 165 (2005) 265-272